## Alkylating Agents in Multiple Myeloma **Key Point:** Melphalan is the gold-standard alkylating agent for multiple myeloma, particularly in older patients and those not eligible for high-dose chemotherapy with autologous stem cell transplantation (ASCT). ### Melphalan: First-Line Choice **High-Yield:** Melphalan + prednisone (MP) has been the backbone of myeloma therapy for decades. It is: - Oral bioavailability (convenient for outpatient management) - Rapid onset of action - Predictable toxicity profile - Cost-effective in resource-limited settings - Standard in non-transplant-eligible patients ### Comparison of Alkylating Agents in Myeloma | Agent | Role in MM | Notes | |-------|-----------|-------| | **Melphalan** | First-line (non-ASCT) | Oral, standard MP regimen | | Cyclophosphamide | Induction (ASCT-eligible) | Used in VCD, PAD regimens; IV preferred | | Chlorambucil | Obsolete | Rarely used; inferior efficacy | | Busulfan | Conditioning only | Reserved for ASCT conditioning | ### Clinical Context **Clinical Pearl:** In India, where ASCT infrastructure may be limited, melphalan remains the most practical first-line alkylating agent. Modern regimens now often combine melphalan with novel agents (bortezomib, lenalidomide, thalidomide) rather than prednisone alone. **Mnemonic:** **MM-Melphalan** — Multiple Myeloma's classic alkylating agent. ### Why Melphalan Over Others 1. **Oral formulation** → better patient compliance 2. **Proven survival benefit** in landmark trials 3. **Acceptable toxicity** with standard supportive care 4. **Cost** — critical in Indian healthcare settings [cite:KD Tripathi 8e Ch 65]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.